Anixa Biosciences, Inc. · NASDAQ:ANIX
Anixa Biosciences — Investor Presentation (August 2020)
19 slides from Anixa Biosciences's investor presentation, Aug 17, 2020
Slide 1: Anixa Biosciences
Aanixa BIOSCIENCES August 13, 2020 NASDAQ:ANIX Amit Kumar Chairmanand CEO ak@anixa.com
Slide 2: Forward-Looking Statements
orward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa Biosciences’ current
Slide 3: Corporate Background
Corporate Background General & Financial Strategy: Low Cost Business Model NASDAQ: ANIX Invent/in-license technology platforms Bay Area, CA Biotech ¢ Develop technology with partners More than 1 year of cash « Leverage existing infrastructure of Capital Efficient Model partner No debt © Maintain low
Slide 4: Three High Value Programs
Three High Value Programs Breast Cancer Vaccine * Immunize against a-Lactalbumin to prevent Triple Negative Breast Cancer (TNBC) and other breast cancers * Worldwide license * Cleveland Clinic collaboration for IND and clinical trial * $6.2 MM DOD grant will fund pre-clinical work and two Ph 1 clini
Slide 5: Leadership Team
Leadership Team Key Members of Management Amit Kumar, PhD, Chairman, CEO and President * Co-Founder, Executive Chairman, Actym Therapeutics * Member, Board of Directors, American Cancer Society * Former President and CEO, CombiMatrix, acquired by Invitae (NASDAQ:NVTA) * Entrepreneur in Residence, Oa
Slide 6: Breast Cancer Vaccine
Breast Cancer Vaccine Inventor and PI: Vincent K. Tuohy, Ph.D. Mort and Iris November Distinguished Chair in Innovative Cancer Research, Cleveland Clinic Retired Tissue Specific Protein * Expressed at periods of life, but no longer expressed as we age ew o-Lactalbumin >" 30) omy) : wget | o | on A r
Slide 7: Vaccination Prevents Breast Cancer
Vaccination Prevents Breast Cancer Vaccinated mice did not exhibit autoimmune damage, while single T-cell infiltrates were seen in non-lactating breast tissue (arrows) Aanixa EFFECTIVE MMTV-neu Mice 100 <— 80 * Vaccinated Controls / \ 100% of a-LACTALBUMIN vaccinated mice did not develop breast canc
Slide 8: Breast Cancer Vaccine Clinical Trial Plan
Breast Cancer Vaccine Clinical Trial Plan Funded by Department of Defense (DOD) Grant $6.2 MM Pre-Clinical Studies GLP Tox Phase 1a Trial IND filin, 5 8 * TNBC patients who have Biase 4) 1a) undergone standard of care * Healthy women with BRCA1 mutations * Will monitor pro-inflammatory T-cell respon
Slide 9: Summary: Breast Cancer Vaccine
Summary: Breast Cancer Vaccine KEY ATTRIBUTES MARKET OPPORTUNITY (Estimates) Prophylactic (preventative) vaccines are administered to all eligible, not the small number of sick patients “Cleveland Clinic collaboration DOD funded program; $6.2 Pre-clinical Expect reimbursement for this vaccine to be
Slide 10: CAR-T Technology: Background & Opportunity
CAR-T Technology: Background & Opportunity CAR- Technology has made great inroads in B-Cell cancers * Durable responses (50-80% of patients) * Multibillion dollar valuations and big pharma deals o Novartis - First approved product by FDA o Kymriah for ALL- Acute Lymphoblastic Leukemia e Second appro
Slide 11: Anixa's Unique CER-T Approach for Solid Tumors
Anixa’s Unique CER-T Approach for Solid Tumors Novartis, JUNO, KITE and others Anixa’s CAR-T Program for Ovarian Cancer working on B-Cell cancers FSHR- Follicle Stimulating Hormone Receptor Chimeric Endocrine Receptor T-Cell Cancerous B-cell CD19 protein — (antigen) scFv-antibody fragment engineered
Slide 12: FSHR ONLY Expressed in Ovaries and Testis
FSHR ONLY Expressed in Ovaries and Testis *In Healthy Humans* 0.002 - Onan Rete Tava * FSHR expressed on the blood vessels 0.0015 \ of many TUMORS 0.001 Relative FSHR mRNA expression ¢ This therapy will be anti-angiogenic 0.0005 - for many types of cancer, enabling a 0 Me I portfolio of therapies fo
Slide 13: Pre-Clinical Data
Pre-Clinical Data FSH-Targeted chimeric receptors re-direct primary human T cells against FSHR+ ovarian cancer cells 707 —=-FSHCER 60-4 -& Mock 4 50: 40 30. 20 10: ty) 31 1:5 1:10 Target:Effector ratio Ovarian Cancer —> Breast Cancer ‘Source: Perales-Puchalt et al. “Follicle-stimulating hormone rece
Slide 14: Our Magic Bullet Responses
Our Magic Bullet Raaspanes Tumors induce rapid Tumor blood vessel growth to nourish themselves + Many tumors have blood vessels where FSHRis expressed even though healthy tissue does not show such expression © Physiologically, FSHR must be helpful in enabling tumors to create vasculature © Outside o
Slide 15: Summary: CAR-T Program
Summary: CAR-T Program * Exclusive worldwide license from The Wistar Institute o Tested human CAR-T in immunocompromised mice against human ovarian cancer o Tested murine CAR-T in immunocompetent mice against murine ovarian cancer o Tested human CAR-T in immunocompromised mice against human breast c
Slide 16: Covid-19 Program
Covid-19 Program ¢ Initiated April 20, 2020 with partner OntoChem, GmbH SARS-CoV-2 Enzymes Virtual Screening & Scoring 1.2 Billion Compounds — Virtual Screening (1.2 BB compounds) — Targets: Main Protease (MP°'°), Endoribonuclease (NSP-15) * In Silico Hits _ 2 F 2 2D and 3-D Binding Pre: In Silico S
Slide 17: Commercial Partnership and Monetization Strategy
Commercial Partnership and Monetization Strategy Aanixa Drug development is risky — We mitigate the risk by diversifying — We also work on programs that are relatively low cost Drugs and vaccines are developed through a three phase human clinical trial process We have capital to complete the Phase 1
Slide 18: Impact of Covid-19 on Anixa's Programs
Impact of Covid-19 on Anixa’s Programs * Impact of Covid-19 — Our Partners (Cleveland Clinic and Moffitt Cancer Center) and multiple vendors have been impacted by the pandemic as well as mandated social distancing constraints — We are trying to mitigate the impacts as much as possible — The pandemic
Slide 19: Anixa's Value-Creating Near-Term Milestones
Anixa’s Value-Creating Near-Term Milestones Breast Cancer Vaccine Filing of IND for clinical trials- 2020 Approval of IND by FDA Patient recruitment First patient dosed and initiation of clinical trial Clinical Data Release Covid-19 Therapeutics Identify additional potential compounds Results of in
Anixa Biosciences — Investor Presentation (August 2020) on 6ix